New antifungal compounds and strategies for treatment of invasive fungal infections in patients with neoplastic diseases.
Walsh
T J
TJ
Infectious Diseases Section, Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Lyman
C A
CA
D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D001393:Azoles / Q000627:therapeutic use; D005437:Flucytosine / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D009181:Mycoses / Q000150:complications / Q000188:drug therapy*; D009369:Neoplasms / Q000150:complications / Q000276:immunology*; D009503:Neutropenia / Q000150:complications*
D000935:Antifungal Agents; D001393:Azoles; D000666:Amphotericin B; D005437:Flucytosine